Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Shenzhen Antiv Pharma Co. Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 examiners and 2 art units, indicating separate examination tracks.
MCDOWELL, BRIAN E is the busiest listed examiner, with 1 pending matter. A coordinated biotechnology position may be useful across the matters, but each response should address its own art-unit record.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
| CHO, DAVID H | 1 | 31.9% | +67.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18902049 | COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF | MCDOWELL, BRIAN E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18902049 | COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF | MCDOWELL, BRIAN E | — |
| 18721842 | CRYSTAL FORM OF NUCLEOSIDE COMPOUND | CHO, DAVID H | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18902049 | COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF | MCDOWELL, BRIAN E | 1624 | §103§112 | Non-Final OA | — | Pending | Sep 30, 2024 |
| 18721842 | CRYSTAL FORM OF NUCLEOSIDE COMPOUND | CHO, DAVID H | 1693 | §112 | Non-Final OA | — | Pending | Jun 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShenzhen Antiv Pharma Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Brian E Mcdowell has the most, with 1 of Shenzhen Antiv Pharma Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
